Wedbush analyst David Nierengarten maintains Inozyme Pharma (NASDAQ:INZY) with a Outperform and announces $15 price target.
Wedbush Maintains Outperform on Inozyme Pharma, Announces $15 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.